Ibruscin have an active component as Ibrutinib which is used to treat mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia and small lymphocytic lymphoma. Ibruscin is also used to treat chronic graft-versus-host disease. Ibruscin provides long term survival benefits to patients with chronic lymphocytic leukemia (CLL). Ibruscin is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with or without 17p deletion, adults with Waldenstrom’s macroglobulinemia (WM), adults with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy, adults with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.It is a first line treatment in those with CLL who require treatment and are newly diagnosed. It may also be used in CLL that relapses.
- Manufactured By: Scindia Pharma
- Active Ingredients: Ibrutinib
- Release Form: Oral Tablets
- Strength: 1 mg
- Packing Size: 10*10 Tablets
Usage: Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who has at least one prior therapy. CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness. The dosage is completely based on the medical condition of patient. Patient’s age, weight, medical condition & response to medicine is considered for dosage and medication. Usually it consume orally once daily with full glass of water. Swallow it whole as do not open, break or chew.
- Dosage: As directed by the physician
- Storage: Keep in cool, dark & dry place.
- Swelling to ankles/legs/feet
- Numbness/tingling of arms/legs
Keep medicine out of reach of Children